Wiley announced on February 17, 2026 that it will expand its Advanced Portfolio of scientific journals with eight new titles by the end of the year, extending a brand that has grown to more than 25 high-impact journals anchored by Advanced Materials and Advanced Science. The expansion moves the portfolio, historically concentrated in materials science and chemistry, into life sciences, health sciences, social sciences, AI, neuroscience, and other interdisciplinary fields at the intersection of human health and technology.
The first of the new titles, Advanced Oncology, opened for submissions the following month. Wiley has also named Advanced Intelligent Discovery, Advanced Robotics Research, and Advanced Chemical Engineering among the forthcoming launches, with additional titles to be announced through the rest of 2026 and further expansion planned in subsequent years.
What Wiley is announcing
Per Wiley’s own newsroom release, the Advanced Portfolio is positioned around rigorous editorial standards combined with what the company describes as a collaborative, author-editor partnership model: authors submit a manuscript once, and Wiley editors work across the portfolio’s journals to route it to the best-fit title, intended to reduce the resubmission and reformatting cycles that come with rejection-and-resubmit workflows at separately run journals. Allyn Molina, Wiley’s Group Vice President of Publishing Development, framed the expansion around researcher demand for “more prestigious yet accessible venues,” and Kirsten Severing, Editor-in-Chief of Advanced Science, described the goal as making the portfolio “a natural home for researchers whose work crosses traditional boundaries.”
This is not Wiley’s first Advanced Portfolio expansion into life and health sciences — the company announced an earlier round of growth in this direction in 2024. The February 2026 announcement is a further, larger extension of that same strategy, with a concrete eight-journal, single-year target attached to it.
Why this matters for researchers and research administrators, not just publishing-industry watchers
A publisher launching new journals is routine trade news on its own. What makes it relevant to anyone advising authors on journal choice — research administrators, library scholarly-communications staff, PI mentors — is what a brand-new journal title means practically in the first one to three years of its life, before it has any track record:
- No Journal Impact Factor at launch. A new journal has no publication history, so it cannot receive a Journal Impact Factor until Clarivate has enough indexed, cited content — typically a minimum of two full calendar years of indexing before a first JIF is assigned. Authors under funder or institutional pressure to publish in JIF-ranked venues should not assume a brand-new Advanced-family title inherits the metrics of flagship titles like Advanced Materials (reported 2025 JCR Impact Factor of 26.8) or Advanced Science. A new title starts from zero, regardless of its brand family.
- Open-access model and APC vary by title, and Wiley’s launch materials do not specify pricing for the new journals. The existing Advanced Portfolio is not uniform: Advanced Science publishes fully open access under a CC-BY license with a five-figure-range article processing charge, while Advanced Materials operates as a hybrid subscription/open-access journal. Wiley’s announcement of the eight new titles did not disclose an open-access model, licensing terms, or APC for any of them. See CASRAI’s guide to APCs and open access for how these charges typically work. Authors and grants/finance administrators budgeting for publication costs — including funder open-access mandates that require CC-BY licensing — should check each new title’s individual policies directly once they publish them, rather than assuming portfolio-wide consistency.
- A cross-portfolio “submit once, route internally” model is a form of cascading peer review. Routing a rejected or better-fitting manuscript to a sister journal within the same publisher, without a fresh submission and full re-review, is a known industry practice (sometimes called cascading or portfolio peer review) used by several large publishers. It can genuinely save authors time, but it also means a manuscript’s ultimate home may be an editorial routing decision rather than a first-choice submission — worth understanding before assuming any exact title from the announcement is where a given manuscript will land.
- New-journal launches are a period of elevated scrutiny risk, unrelated to Wiley specifically. Any new journal — from any publisher — takes time to build a track record of editorial rigor, indexing, and reviewer pool depth. Research-integrity and library guidance generally advises checking a new journal’s editorial board, indexing status, and peer-review policies directly before submitting or recommending it to a mentee, exactly as one would for any unfamiliar title, brand-name affiliation notwithstanding — see CASRAI’s guidance on identifying predatory journals and publishers for the general due-diligence checklist.
Context: why publishers are expanding branded journal families
The Advanced Portfolio expansion sits inside a broader industry pattern of publishers building multi-journal brand families with shared editorial infrastructure and cross-submission routing, rather than launching each new title as a fully independent operation. For a publisher, this spreads fixed editorial and production costs across more titles and lets a strong flagship brand (like Advanced Materials) lend credibility to adjacent new launches. For funders and institutions, it is a reminder that a journal’s brand family is not a substitute for evaluating each title on its own indexing, editorial board, and — where OA mandates apply — licensing terms.
What to watch through the rest of 2026
Wiley has said the remaining new titles beyond the four named so far (Advanced Oncology, Advanced Intelligent Discovery, Advanced Robotics Research, Advanced Chemical Engineering) will be announced later in the year. Researchers and administrators tracking journal options in oncology, AI, robotics, and chemical engineering should watch for each title’s specific submission guidelines, peer-review model, and — critically for OA-mandate compliance — its licensing and APC terms once published, rather than relying on the launch announcement alone.
